Celltrion reported on the 1st that it had submitted an application for approval of the biosimilar "CT-P16" of Avastin (Bevacizumab), Roche's colorectal cancer treatment, to the MFDS and the U.S. FDA.

According to the MFDS on the 19th, Celltrion's Avastin biosimilar, which was recently applied for permission, is Vegzelma.

This is the first time that the brand name of the development project CT-P16 has been known. Celltrion also registered trademark rights for Vegzelma with the Korean Intellectual Property Office in November last year.

Celltrion has conducted a global clinical trial on a total of 689 people in 20 countries in Europe, South America, and Asia since 2018 and app